These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 36621910)
1. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry. Kamphuis E; Loman L; Han HL; Romeijn GLE; Politiek K; Schuttelaar MLA Contact Dermatitis; 2023 May; 88(5):351-362. PubMed ID: 36621910 [TBL] [Abstract][Full Text] [Related]
2. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation. Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324 [TBL] [Abstract][Full Text] [Related]
3. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry. Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA Contact Dermatitis; 2022 Aug; 87(2):185-191. PubMed ID: 35279856 [TBL] [Abstract][Full Text] [Related]
4. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice. Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732 [TBL] [Abstract][Full Text] [Related]
5. Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials. Simpson EL; Rahawi K; Hu X; Chu AD; Nduaka C; Jazayeri S; Lio P; Lynde C; Schuttelaar MLA J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1863-1870. PubMed ID: 37184290 [TBL] [Abstract][Full Text] [Related]
6. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008 [TBL] [Abstract][Full Text] [Related]
7. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry. Kamphuis E; Boesjes CM; Loman L; Kamsteeg M; Haeck I; Van Lynden-van Nes AMT; Politiek K; Van der Gang LF; De Graaf M; De Bruin-Weller MS; Schuttelaar MLA Acta Derm Venereol; 2024 Feb; 104():adv19454. PubMed ID: 38323500 [TBL] [Abstract][Full Text] [Related]
8. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. Hagino T; Saeki H; Fujimoto E; Kanda N J Dermatolog Treat; 2024 Dec; 35(1):2344591. PubMed ID: 38653561 [TBL] [Abstract][Full Text] [Related]
9. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257 [TBL] [Abstract][Full Text] [Related]
10. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009 [TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. Hagino T; Saeki H; Kanda N J Dermatol; 2022 Nov; 49(11):1158-1167. PubMed ID: 35986480 [TBL] [Abstract][Full Text] [Related]
13. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. Silverberg JI; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Costanzo A; Rosmarin D; Lynde C; Liu J; Gamelli A; Zeng J; Ladizinski B; Chu AD; Reich K J Allergy Clin Immunol; 2022 Mar; 149(3):977-987.e14. PubMed ID: 34403658 [TBL] [Abstract][Full Text] [Related]
14. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1. Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473 [TBL] [Abstract][Full Text] [Related]
15. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977 [TBL] [Abstract][Full Text] [Related]
16. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Simpson EL; Prajapati VH; Leshem YA; Chovatiya R; de Bruin-Weller MS; Ständer S; Pink AE; Calimlim BM; Lee WJ; Teixeira H; Ladizinski B; Hu X; Yang Y; Liu Y; Liu M; Grada A; Platt AM; Silverberg JI Dermatol Ther (Heidelb); 2024 May; 14(5):1127-1144. PubMed ID: 38696027 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients. Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies. Schmid-Grendelmeier P; Gooderham MJ; Hartmann K; Konstantinou GN; Fellmann M; Koulias C; Clibborn C; Biswas P; Brunner PM Allergy; 2024 Jan; 79(1):174-183. PubMed ID: 37988255 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan. Hagino T; Hamada R; Yoshida M; Saeki H; Fujimoto E; Kanda N Clin Drug Investig; 2024 Apr; 44(4):261-269. PubMed ID: 38446396 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. Paller AS; Ladizinski B; Mendes-Bastos P; Siegfried E; Soong W; Prajapati VH; Lio P; Thyssen JP; Simpson EL; Platt AM; Raymundo EM; Liu J; Calimlim BM; Huang X; Gu Y; Hu X; Yang Y; Su JC; Zheng M; Yamamoto-Hanada K; Teixeira HD; Irvine AD JAMA Dermatol; 2023 May; 159(5):526-535. PubMed ID: 37043227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]